| Date | Title | | | 05/15/13 | Synta Announces Presentations at the 2013 American Society for Clinical Oncology (ASCO) Annual Meeting| LEXINGTON, Mass.--(BUSINESS WIRE)--May. 15, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced scheduled
presentations at the 2013 American Society for Clinical Oncology (ASCO)
Annual Meeting, which is taking place May 31 – June 4 in Chicago.
GALAXY-1 interim results
“A randomized study of ganetespib, a heat shock protein 90 inhibitor, in
combination with docetaxel versus docetaxel alone for second-line
therapy of lu... |
|  | | 04/30/13 | Synta Provides Clinical Updates and Reports First Quarter 2013 Financial Results| LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 30, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided clinical
updates and reported financial results for the first quarter ended March
31, 2013.
Clinical Updates
Interim results from the randomized GALAXY-1 Phase 2b/3 trial, which
compares docetaxel with and without Synta’s investigational Hsp90
inhibitor ganetespib for the second-line treatment of advanced non-small
ce... |
| | | 04/22/13 | Synta Announces First Patients Treated in Pivotal GALAXY-2 Trial Evaluating Ganetespib in Advanced Non-Small Cell Lung Cancer| LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 22, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that the
first patients have been treated in the randomized GALAXY-2 Phase 3
trial designed to evaluate docetaxel plus ganetespib, its
investigational Hsp90 inhibitor, versus docetaxel alone for the
second-line treatment of non-small cell lung adenocarcinoma. The study
will enroll approximately 500 patients from about 140 cancer treatment
... |
| | | 04/16/13 | Synta to Host Conference Call and Webcast of First Quarter 2013 Financial Results on April 30, 2013| LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 16, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will
release its first quarter 2013 financial results before the market opens
on Tuesday, April 30, 2013.
Following the issuance of the press release, management will conduct a
conference call at 10:00 a.m. (EDT) that morning to review the Company's
first quarter financial results. The conference call will be webcast
live o... |
| | | 04/05/13 | Synta Announces Presentations at the 2013 Annual Meeting of the American Association of Cancer Research| LEXINGTON, Mass.--(BUSINESS WIRE)--Apr. 5, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) announced today that poster
presentations related to studies with ganetespib, a selective Hsp90
inhibitor in clinical development by the company, will be presented at
the 2013 Annual Meeting of the American Association of Cancer Research
in Washington, D.C. Presentations include:
Inhibition of mTOR enhances the activity of HSP90 inhibitors in part
... |
| | | 03/14/13 | Synta Provides Company Updates and Reports Fourth Quarter and Year-End 2012 Financial Results|
-- Expects mid-year overall survival results from the GALAXY-1
trial for ganetespib in second-line non-small cell lung cancer –
-- Expects enrollment of the pivotal GALAXY-2 Phase 3 trial to
commence this month --
-- Announces key addition to executive management team –
LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 14, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today provided an update on
recent progress with its clini... |
| | | 03/13/13 | Synta Announces Appointment of Sumant Ramachandra, M.D., Ph.D. as President, Research and Development| LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 13, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the
appointment of Dr. Sumant Ramachandra as President, Research and
Development.
Prior to Synta, Dr. Ramachandra was Senior Vice President, Research and
Development (R&D), Regulatory and Medical Affairs, and Chief Scientific
Officer of Hospira, a specialty pharmaceuticals and medical device
company. At Hospira, Dr. Ramacha... |
| | | 02/25/13 | Synta to Host Conference Call and Webcast of Fourth Quarter and Year-End 2012 Financial Results on March 14, 2013| LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 25, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that it will
release its fourth quarter and year-end 2012 financial results before
the market opens on Thursday, March 14, 2013.
Following the issuance of the press release regarding the financial
results, management will conduct a conference call at 10:00 a.m. (EST)
that morning. The call will be webcast
live over the Internet... |
| | | 02/11/13 | Synta to Present at Upcoming Conferences| LEXINGTON, Mass.--(BUSINESS WIRE)--Feb. 11, 2013--
Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the
Company will present at the following investor conferences:
Leerink
Swann Global Healthcare Conference in New York
Wednesday,
February 13, at 8:30 a.m. (EST)
Cowen
and Company 33rd Annual Healthcare Conference in Boston
Monday,
March 4, at 3:30 p.m. (EST)
Barclays
Global Healthcar... |
| |
|
